EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression

Chunxiao Dai, Yaoyang Fu, Xuanwei Li, Meihua Lin, Yinbo Li, Xiao Li, Keke Huang, Chengcheng Zhou, Jian Xie, Qingwei Zhao, Shaohua Hu

Journal of Zhejiang University-SCIENCE B · 2025-01 · 26 (1) · 26-38

DOI: 10.1631/jzus.b2400470 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Zhejiang University-SCIENCE B, online erschienen am 20.01.2025. Verfasst von Chunxiao Dai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. Hauptthemen laut MEDLINE: Bipolar Disorder, Vortioxetine, Sulfides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Construction Fund of Key Medical Disciplines of Hangzhou, the National Key Research and Development Program of China, the Zhejiang Provincial Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderVortioxetineSulfidesHumansMaleFemaleMiddle AgedAdultValproic AcidLurasidone HydrochlorideProspective StudiesTreatment OutcomePilot ProjectsDrug Therapy, CombinationAntidepressive Agents

Stichwörter der Autor:innen

Bipolar II depressionCombinationLurasidoneVortioxetine

Substanzen

VortioxetineValproic AcidLurasidone HydrochlorideSulfidesAntidepressive Agents

Autor:innen und Institutionen

  • Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
  • Department of Clinical Psychology, Hangzhou First People's Hospital, Hangzhou 310006, China.
  • Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
  • Fuyang Third People's Hospital, Hangzhou 311402, China.
  • Department of Clinical Psychology, Hangzhou First People's Hospital, Hangzhou 310006, China. srxjian@163.com.
  • Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. srxjian@163.com.

Förderung

  • the Construction Fund of Key Medical Disciplines of Hangzhou
  • the National Key Research and Development Program of China
  • the Zhejiang Provincial Key Research and Development Program
  • the Research Project of Jinan Microecological Biomedicine Shandong Laboratory
  • the Leading Talent of Scientific and Technological Innovation‒"Ten Thousand Talents Program" of Zhejiang Province
  • the Innovation Team for Precision Diagnosis and Treatment of Major Brain Diseases
  • the Chinese Medical Education Association

Zitieren

APA

Dai, C., Fu, Y., Li, X., Lin, M., Li, Y., Li, X., Huang, K., Zhou, C., Xie, J., Zhao, Q., & Hu, S. (2025). Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression. Journal of Zhejiang University-SCIENCE B, 26(1), 26-38. https://doi.org/10.1631/jzus.b2400470

Vancouver

Dai C, Fu Y, Li X, Lin M, Li Y, Li X, et al. Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression. Journal of Zhejiang University-SCIENCE B. 2025;26(1):26-38. doi:10.1631/jzus.b2400470

BibTeX
@article{Dai2025,
  author = {Dai, Chunxiao and Fu, Yaoyang and Li, Xuanwei and Lin, Meihua and Li, Yinbo and Li, Xiao and Huang, Keke and Zhou, Chengcheng and Xie, Jian and Zhao, Qingwei and Hu, Shaohua},
  title = {Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression},
  journal = {Journal of Zhejiang University-SCIENCE B},
  year = {2025},
  volume = {26},
  number = {1},
  pages = {26--38},
  doi = {10.1631/jzus.b2400470}
}
Kostenlos starten →